Cephalalgia. 2026 Nov;46(11):3331024261499722. doi: 10.1177/03331024261499722. Epub 2026 Nov 17.
ABSTRACT
BackgroundThese post-hoc analyses evaluated the proportions of participants who experienced sustained responses to atogepant, an oral calcitonin gene-related peptide receptor antagonist, over two 3-month, double-blind, randomized controlled trials (RCTs) (ELEVATE and PROGRESS) and a 12-month interim analysis of the open-label extension (OLE) study that was composed of participants from ELEVATE and PROGRESS.MethodsPost-hoc analyses were conducted to assess the sustained responses with atogepant 60 mg once daily (QD). Sustained responses, based on predefined thresholds for reductions in monthly migraine days (MMDs) over a specified period, allow for evaluation of long-term efficacy of atogepant. The ELEVATE trial enrolled participants with episodic migraine who had inadequate response to two to four classes of conventional oral preventive medications; the PROGRESS trial enrolled participants with chronic migraine. These post-hoc analyses were conducted in the modified intent-to-treat (mITT) populations for the atogepant 60 mg QD group from the RCTs ELEVATE (151 participants) and PROGRESS (256 participants). An initial response was defined as ≥ 50%, ≥ 75%, or 100% reduction in MMDs from baseline to month 1 of each respective RCT. Proportions of participants who maintained or exceeded their month 1 response threshold through months 2 and 3 of each RCT were calculated. For the OLE, (ELEVATE, 240 participants and PROGRESS, 284 participants in the mITT population), initial response was defined as ≥ 50%, ≥ 75%, or 100% reduction in MMDs from baseline to month 4 of the OLE. Proportions of participants who maintained or exceeded their month 4 response threshold at month 12 of the OLE were calculated.ResultsIn the two 12-week RCTs, 61.3% (49/80) of ELEVATE participants and 74.2% (69/93) of PROGRESS participants who experienced an initial ≥ 50% reduction in MMDs during month 1 of each RCT continued to have a ≥ 50% reduction in MMDs during both months 2 and 3. During the OLE, 83.4% (121/145) of participants from ELEVATE and 88.5% (131/148) of participants from PROGRESS who experienced a ≥ 50% reduction in MMDs from the RCT baseline to month 4 of the OLE continued to have a ≥ 50% reduction in MMDs at month 12 of the OLE. High rates of sustained responses were similarly observed across the other response thresholds.ConclusionsParticipants who experienced an initial clinically meaningful response with atogepant continued to experience sustained responses over the 3-month RCTs as well as at 12 months of their OLE study.Trial registrationELEVATE (3101-304-002), NCT04740827 (https://clinicaltrials.gov/study/NCT04740827?cond = ELEVATE,%20NCT04740827&rank=1&tab = results), 2021-02-05; PROGRESS (3101-303-002), NCT03855137 (https://clinicaltrials.gov/study/NCT03855137?cond = PROGRESS,%20NCT03855137&rank=1&tab = results); 2019-02-25; Open-label Extension (3101-312-002), NCT04686136 (https://clinicaltrials.gov/study/NCT04686136?cond = NCT04686136&rank=1); 2021-02-19.
PMID:43042641 | DOI:10.1177/03331024261499722
